A change from gonadotropin releasing hormone antagonist to gonadotropin releasing hormone agonist therapy does not affect the oncological outcomes in hormone sensitive prostate cancer

BACKGROUND: The aim of our retrospective study was to evaluate the 5-year survival and time to castration resistant prostate cancer in patients with hormone sensitive prostate cancer treated with the gonadotropin releasing hormone antagonist, degarelix. Another aim was to evaluate the effects of cha...

Полное описание

Сохранить в:
Библиографические подробности
Опубликовано в: :Basic Clin Androl
Главные авторы: Asakawa, Jumpei, Iguchi, Taro, Tamada, Satoshi, Yasuda, Sayaka, Ninomiya, Noriko, Kato, Minoru, Yamasaki, Takeshi, Ohmachi, Tetusji, Nakatani, Tatsuya
Формат: Artigo
Язык:Inglês
Опубликовано: BioMed Central 2018
Предметы:
Research Article
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC6050721/
https://ncbi.nlm.nih.gov/pubmed/30026950
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12610-018-0074-2
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы